PDGFR Inhibitor
-
PDGFR Inhibitor (292)
-
Lenvatinib
0 ImagesSynonyms: E7080; MK-7902 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Nintedanib
0 ImagesSynonyms: BIBF 1120; IntedanibNintedanib (BIBF 1120; Intedanib) is an orally active receptor tyrosine kinase inhibitor. Nintedanib inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Imatinib
0 ImagesSynonyms: STI571; CGP-57148BImatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Sunitinib
0 ImagesSynonyms: SU 11248Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Regorafenib
0 ImagesSynonyms: BAY 73-4506 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- Ponatinib
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- Axitinib
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- Pazopanib
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Avapritinib
0 ImagesSynonyms: BLU-285Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- SU 5402
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Nintedanib esylate
0 ImagesSynonyms: BIBF 1120 esylate; Intedanib esylateNintedanib esylate (BIBF 1120 esylate; Intedanib esylate) is an orally active receptor tyrosine kinase inhibitor. Nintedanib esylate inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib esylate exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib esylate ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib esylate can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Lenvatinib mesylate
0 ImagesSynonyms: E7080 mesylate; MK-7902 mesylate -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Luminespib
0 ImagesSynonyms: VER-52296; AUY922; NVP-AUY922Luminespib (VER-52296) is a potent HSP90 inhibitor, with IC50 values of 7.8 nM for HSP90α and 21 nM for HSP90β. By inhibiting HSP90, Luminespib blocks multiple signaling pathways—mediated by EGF, VEGF, and PDGF—that promote cell proliferation, metastasis, and angiogenesis; consequently, it suppresses cancer cell proliferation, migration, and invasion, as well as the formation of new blood vessels. Luminespib can be used in research on cancers such as pancreatic cancer and prostate cancer.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- CP-673451
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- Imatinib Mesylate
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Crenolanib
0 ImagesSynonyms: CP-868596 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Sunitinib Malate
0 ImagesSynonyms: SU 11248 MalateSunitinib (SU 11248) Malat is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib Malat, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Ripretinib
0 ImagesSynonyms: DCC-2618Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Linifanib
0 ImagesSynonyms: ABT-869; AL-39324Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Masitinib
0 ImagesSynonyms: AB1010Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity.
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -